These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
Edwards Lifesciences Corporation EW reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.
Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.
Why Is Edwards Lifesciences (EW) Stock Down 22% Today?
Edwards Lifesciences (NYSE: EW ) stock is down on Thursday after the heart disease care company announced earnings for its second quarter of 2024. That earnings report starts with its adjusted EPS of 70 cents.
Edwards Lifesciences Stock Plunges 24% After Earnings. What Wall Street Thinks.
The medical-technologies company misses second-quarter sales estimates.
Edwards Lifesciences Corporation INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Edwards Lifesciences (EW)
NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.
Edwards Lifesciences Corporation (EW) Q2 2024 Earnings Call Transcript
Edwards Lifesciences Corporation (NYSE:EW ) Q2 2024 Earnings Conference Call July 24, 2024 5:00 PM ET Company Participants Mark Wilterding - SVP & IR Bernard Zovighian - CEO Scott Ullem - CFO Larry Wood - Group President of TAVR and Surgical Structural Heart Daveen Chopra - Global Leader of TMTT Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan David Roman - Goldman Sachs Joshua Jennings - TD Cowen Travis Steed - Bank of America Matthew Taylor - Jefferies Vijay Kumar - Evercore ISI Patrick Wood - Morgan Stanley Operator Greetings, and welcome to the Edwards Lifesciences Second Quarter 2024 Results. At this time, all participants are in a listen-only mode.
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Edwards Lifesciences (EW) Q2 Earnings Match Estimates
Edwards Lifesciences (EW) came out with quarterly earnings of $0.70 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.66 per share a year ago.
Edwards Lifesciences misses Q2 revenue estimates on weak demand for heart devices
Edwards Lifesciences missed second-quarter revenue estimates on Thursday, hurt by lower-than-expected demand for its artificial heart valves.
Edwards Lifesciences Corporation Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - EW
NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Edwards Lifesciences Corporation ("Edwards Lifesciences") (NYSE:EW) concerning possible violations of federal securities laws. On October 28, 2022, Edwards announced 3Q 2022 financial results that missed revenue estimates and then lowered revenue guidance for the 4Q.
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.
Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
